Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares saw unusually-strong trading volume on Friday after Royal Bank of Canada raised their price target on the stock to $91.00. Royal Bank of Canada currently has an outperform rating on the stock. Approximately 4,119,632 shares were traded during mid-day trading, an increase of 325% from the previous session’s volume of 969,146 shares.The stock last traded at $69.89 and had previously closed at $68.15.
Other equities analysts have also issued research reports about the company. SunTrust Banks reissued a “buy” rating and set a $80.00 target price on shares of Agios Pharmaceuticals in a research note on Wednesday, October 4th. Oppenheimer set a $83.00 target price on Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, December 26th. Canaccord Genuity set a $90.00 target price on Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, December 12th. Cann reissued a “buy” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, December 5th. Finally, Zacks Investment Research raised Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $68.00 target price on the stock in a research note on Tuesday, January 9th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $77.64.
In other Agios Pharmaceuticals news, CEO David P. Schenkein sold 53,000 shares of the company’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $73.16, for a total transaction of $3,877,480.00. Following the sale, the chief executive officer now owns 53,000 shares in the company, valued at approximately $3,877,480. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO David P. Schenkein sold 6,000 shares of the company’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $63.85, for a total value of $383,100.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 80,130 shares of company stock worth $5,561,250. 5.43% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. California Public Employees Retirement System increased its holdings in Agios Pharmaceuticals by 2.3% during the 2nd quarter. California Public Employees Retirement System now owns 34,900 shares of the biopharmaceutical company’s stock worth $1,796,000 after purchasing an additional 800 shares during the period. UBS Asset Management Americas Inc. increased its holdings in Agios Pharmaceuticals by 3.2% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 27,088 shares of the biopharmaceutical company’s stock worth $1,394,000 after purchasing an additional 852 shares during the period. Amalgamated Bank increased its holdings in Agios Pharmaceuticals by 12.9% during the 3rd quarter. Amalgamated Bank now owns 7,827 shares of the biopharmaceutical company’s stock worth $522,000 after purchasing an additional 897 shares during the period. Bank of Montreal Can increased its holdings in Agios Pharmaceuticals by 74.8% during the 4th quarter. Bank of Montreal Can now owns 3,551 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 1,520 shares during the period. Finally, Nationwide Fund Advisors increased its holdings in Agios Pharmaceuticals by 37.8% during the 3rd quarter. Nationwide Fund Advisors now owns 6,344 shares of the biopharmaceutical company’s stock worth $423,000 after purchasing an additional 1,740 shares during the period. Institutional investors own 94.32% of the company’s stock.
The stock has a market cap of $3,480.00, a price-to-earnings ratio of -11.15 and a beta of 1.83.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) EPS for the quarter, beating analysts’ consensus estimates of ($1.78) by $0.19. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The business had revenue of $11.35 million for the quarter, compared to the consensus estimate of $10.85 million. During the same quarter in the prior year, the business posted ($1.63) EPS. The business’s revenue for the quarter was up 26.4% on a year-over-year basis. sell-side analysts expect that Agios Pharmaceuticals Inc will post -6.59 earnings per share for the current year.
WARNING: “Agios Pharmaceuticals (AGIO) Sees Strong Trading Volume Following Analyst Upgrade” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/20/agios-pharmaceuticals-agio-sees-strong-trading-volume-following-analyst-upgrade.html.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.